NASH Drugs-United States Market Status and Trend Report 2013-2023
Report Summary
NASH Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on NASH Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of NASH Drugs 2013-2017, and development forecast 2018-2023
Main market players of NASH Drugs in United States, with company and product introduction, position in the NASH Drugs market
Market status and development trend of NASH Drugs by types and applications
Cost and profit status of NASH Drugs, and marketing status
Market growth drivers and challenges
The report segments the United States NASH Drugs market as:
United States NASH Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States NASH Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
PPAR Agonist
FXR Agonist
Caspase Inhibitor
PDE Inhibitor
Other
United States NASH Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
NASH
United States NASH Drugs Market: Players Segment Analysis (Company and Product introduction, NASH Drugs Sales Volume, Revenue, Price and Gross Margin):
Galmed
Intercept
Tobira
Genfit
Conatus
Galectin
Gilead
NuSirt
MediciNova
Shire
Novo Nordisk
Raptor Pharmaceuticals
Zydus Cadila
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
NASH Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on NASH Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of NASH Drugs 2013-2017, and development forecast 2018-2023
Main market players of NASH Drugs in United States, with company and product introduction, position in the NASH Drugs market
Market status and development trend of NASH Drugs by types and applications
Cost and profit status of NASH Drugs, and marketing status
Market growth drivers and challenges
The report segments the United States NASH Drugs market as:
United States NASH Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States NASH Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
PPAR Agonist
FXR Agonist
Caspase Inhibitor
PDE Inhibitor
Other
United States NASH Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
NASH
United States NASH Drugs Market: Players Segment Analysis (Company and Product introduction, NASH Drugs Sales Volume, Revenue, Price and Gross Margin):
Galmed
Intercept
Tobira
Genfit
Conatus
Galectin
Gilead
NuSirt
MediciNova
Shire
Novo Nordisk
Raptor Pharmaceuticals
Zydus Cadila
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF NASH DRUGS
1.1 Definition of NASH Drugs in This Report
1.2 Commercial Types of NASH Drugs
1.2.1 PPAR Agonist
1.2.2 FXR Agonist
1.2.3 Caspase Inhibitor
1.2.4 PDE Inhibitor
1.2.5 Other
1.3 Downstream Application of NASH Drugs
1.3.1 NASH
1.4 Development History of NASH Drugs
1.5 Market Status and Trend of NASH Drugs 2013-2023
1.5.1 United States NASH Drugs Market Status and Trend 2013-2023
1.5.2 Regional NASH Drugs Market Status and Trend 2013-2023
CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of NASH Drugs in United States 2013-2017
2.2 Consumption Market of NASH Drugs in United States by Regions
2.2.1 Consumption Volume of NASH Drugs in United States by Regions
2.2.2 Revenue of NASH Drugs in United States by Regions
2.3 Market Analysis of NASH Drugs in United States by Regions
2.3.1 Market Analysis of NASH Drugs in New England 2013-2017
2.3.2 Market Analysis of NASH Drugs in The Middle Atlantic 2013-2017
2.3.3 Market Analysis of NASH Drugs in The Midwest 2013-2017
2.3.4 Market Analysis of NASH Drugs in The West 2013-2017
2.3.5 Market Analysis of NASH Drugs in The South 2013-2017
2.3.6 Market Analysis of NASH Drugs in Southwest 2013-2017
2.4 Market Development Forecast of NASH Drugs in United States 2018-2023
2.4.1 Market Development Forecast of NASH Drugs in United States 2018-2023
2.4.2 Market Development Forecast of NASH Drugs by Regions 2018-2023
CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES
3.1 Whole United States Market Status by Types
3.1.1 Consumption Volume of NASH Drugs in United States by Types
3.1.2 Revenue of NASH Drugs in United States by Types
3.2 United States Market Status by Types in Major Countries
3.2.1 Market Status by Types in New England
3.2.2 Market Status by Types in The Middle Atlantic
3.2.3 Market Status by Types in The Midwest
3.2.4 Market Status by Types in The West
3.2.5 Market Status by Types in The South
3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of NASH Drugs in United States by Types
CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of NASH Drugs in United States by Downstream Industry
4.2 Demand Volume of NASH Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of NASH Drugs by Downstream Industry in New England
4.2.2 Demand Volume of NASH Drugs by Downstream Industry in The Middle Atlantic
4.2.3 Demand Volume of NASH Drugs by Downstream Industry in The Midwest
4.2.4 Demand Volume of NASH Drugs by Downstream Industry in The West
4.2.5 Demand Volume of NASH Drugs by Downstream Industry in The South
4.2.6 Demand Volume of NASH Drugs by Downstream Industry in Southwest
4.3 Market Forecast of NASH Drugs in United States by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NASH DRUGS
5.1 United States Economy Situation and Trend Overview
5.2 NASH Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 NASH DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES
6.1 Sales Volume of NASH Drugs in United States by Major Players
6.2 Revenue of NASH Drugs in United States by Major Players
6.3 Basic Information of NASH Drugs by Major Players
6.3.1 Headquarters Location and Established Time of NASH Drugs Major Players
6.3.2 Employees and Revenue Level of NASH Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 NASH DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Galmed
7.1.1 Company profile
7.1.2 Representative NASH Drugs Product
7.1.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Galmed
7.2 Intercept
7.2.1 Company profile
7.2.2 Representative NASH Drugs Product
7.2.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Intercept
7.3 Tobira
7.3.1 Company profile
7.3.2 Representative NASH Drugs Product
7.3.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Tobira
7.4 Genfit
7.4.1 Company profile
7.4.2 Representative NASH Drugs Product
7.4.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Genfit
7.5 Conatus
7.5.1 Company profile
7.5.2 Representative NASH Drugs Product
7.5.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Conatus
7.6 Galectin
7.6.1 Company profile
7.6.2 Representative NASH Drugs Product
7.6.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Galectin
7.7 Gilead
7.7.1 Company profile
7.7.2 Representative NASH Drugs Product
7.7.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Gilead
7.8 NuSirt
7.8.1 Company profile
7.8.2 Representative NASH Drugs Product
7.8.3 NASH Drugs Sales, Revenue, Price and Gross Margin of NuSirt
7.9 MediciNova
7.9.1 Company profile
7.9.2 Representative NASH Drugs Product
7.9.3 NASH Drugs Sales, Revenue, Price and Gross Margin of MediciNova
7.10 Shire
7.10.1 Company profile
7.10.2 Representative NASH Drugs Product
7.10.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Shire
7.11 Novo Nordisk
7.11.1 Company profile
7.11.2 Representative NASH Drugs Product
7.11.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.12 Raptor Pharmaceuticals
7.12.1 Company profile
7.12.2 Representative NASH Drugs Product
7.12.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Raptor Pharmaceuticals
7.13 Zydus Cadila
7.13.1 Company profile
7.13.2 Representative NASH Drugs Product
7.13.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Zydus Cadila
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NASH DRUGS
8.1 Industry Chain of NASH Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NASH DRUGS
9.1 Cost Structure Analysis of NASH Drugs
9.2 Raw Materials Cost Analysis of NASH Drugs
9.3 Labor Cost Analysis of NASH Drugs
9.4 Manufacturing Expenses Analysis of NASH Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF NASH DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of NASH Drugs in This Report
1.2 Commercial Types of NASH Drugs
1.2.1 PPAR Agonist
1.2.2 FXR Agonist
1.2.3 Caspase Inhibitor
1.2.4 PDE Inhibitor
1.2.5 Other
1.3 Downstream Application of NASH Drugs
1.3.1 NASH
1.4 Development History of NASH Drugs
1.5 Market Status and Trend of NASH Drugs 2013-2023
1.5.1 United States NASH Drugs Market Status and Trend 2013-2023
1.5.2 Regional NASH Drugs Market Status and Trend 2013-2023
CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of NASH Drugs in United States 2013-2017
2.2 Consumption Market of NASH Drugs in United States by Regions
2.2.1 Consumption Volume of NASH Drugs in United States by Regions
2.2.2 Revenue of NASH Drugs in United States by Regions
2.3 Market Analysis of NASH Drugs in United States by Regions
2.3.1 Market Analysis of NASH Drugs in New England 2013-2017
2.3.2 Market Analysis of NASH Drugs in The Middle Atlantic 2013-2017
2.3.3 Market Analysis of NASH Drugs in The Midwest 2013-2017
2.3.4 Market Analysis of NASH Drugs in The West 2013-2017
2.3.5 Market Analysis of NASH Drugs in The South 2013-2017
2.3.6 Market Analysis of NASH Drugs in Southwest 2013-2017
2.4 Market Development Forecast of NASH Drugs in United States 2018-2023
2.4.1 Market Development Forecast of NASH Drugs in United States 2018-2023
2.4.2 Market Development Forecast of NASH Drugs by Regions 2018-2023
CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES
3.1 Whole United States Market Status by Types
3.1.1 Consumption Volume of NASH Drugs in United States by Types
3.1.2 Revenue of NASH Drugs in United States by Types
3.2 United States Market Status by Types in Major Countries
3.2.1 Market Status by Types in New England
3.2.2 Market Status by Types in The Middle Atlantic
3.2.3 Market Status by Types in The Midwest
3.2.4 Market Status by Types in The West
3.2.5 Market Status by Types in The South
3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of NASH Drugs in United States by Types
CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of NASH Drugs in United States by Downstream Industry
4.2 Demand Volume of NASH Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of NASH Drugs by Downstream Industry in New England
4.2.2 Demand Volume of NASH Drugs by Downstream Industry in The Middle Atlantic
4.2.3 Demand Volume of NASH Drugs by Downstream Industry in The Midwest
4.2.4 Demand Volume of NASH Drugs by Downstream Industry in The West
4.2.5 Demand Volume of NASH Drugs by Downstream Industry in The South
4.2.6 Demand Volume of NASH Drugs by Downstream Industry in Southwest
4.3 Market Forecast of NASH Drugs in United States by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NASH DRUGS
5.1 United States Economy Situation and Trend Overview
5.2 NASH Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 NASH DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES
6.1 Sales Volume of NASH Drugs in United States by Major Players
6.2 Revenue of NASH Drugs in United States by Major Players
6.3 Basic Information of NASH Drugs by Major Players
6.3.1 Headquarters Location and Established Time of NASH Drugs Major Players
6.3.2 Employees and Revenue Level of NASH Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 NASH DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Galmed
7.1.1 Company profile
7.1.2 Representative NASH Drugs Product
7.1.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Galmed
7.2 Intercept
7.2.1 Company profile
7.2.2 Representative NASH Drugs Product
7.2.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Intercept
7.3 Tobira
7.3.1 Company profile
7.3.2 Representative NASH Drugs Product
7.3.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Tobira
7.4 Genfit
7.4.1 Company profile
7.4.2 Representative NASH Drugs Product
7.4.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Genfit
7.5 Conatus
7.5.1 Company profile
7.5.2 Representative NASH Drugs Product
7.5.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Conatus
7.6 Galectin
7.6.1 Company profile
7.6.2 Representative NASH Drugs Product
7.6.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Galectin
7.7 Gilead
7.7.1 Company profile
7.7.2 Representative NASH Drugs Product
7.7.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Gilead
7.8 NuSirt
7.8.1 Company profile
7.8.2 Representative NASH Drugs Product
7.8.3 NASH Drugs Sales, Revenue, Price and Gross Margin of NuSirt
7.9 MediciNova
7.9.1 Company profile
7.9.2 Representative NASH Drugs Product
7.9.3 NASH Drugs Sales, Revenue, Price and Gross Margin of MediciNova
7.10 Shire
7.10.1 Company profile
7.10.2 Representative NASH Drugs Product
7.10.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Shire
7.11 Novo Nordisk
7.11.1 Company profile
7.11.2 Representative NASH Drugs Product
7.11.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.12 Raptor Pharmaceuticals
7.12.1 Company profile
7.12.2 Representative NASH Drugs Product
7.12.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Raptor Pharmaceuticals
7.13 Zydus Cadila
7.13.1 Company profile
7.13.2 Representative NASH Drugs Product
7.13.3 NASH Drugs Sales, Revenue, Price and Gross Margin of Zydus Cadila
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NASH DRUGS
8.1 Industry Chain of NASH Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NASH DRUGS
9.1 Cost Structure Analysis of NASH Drugs
9.2 Raw Materials Cost Analysis of NASH Drugs
9.3 Labor Cost Analysis of NASH Drugs
9.4 Manufacturing Expenses Analysis of NASH Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF NASH DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
